Tegaserod in constipation associated with Parkinson disease.
Impaired gastrointestinal motility and constipation are common problems in Parkinson disease (PD). Many patients with PD continue to experience constipation, despite multiple interventions (dietary modification, bulk-forming agents, stool softeners, and laxatives). Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation. We report our experience with tegaserod in 5 patients with PD-associated constipation. Tegaserod was well tolerated and improved both bowel movement frequency and stool consistency in most of our patients. Further trials with tegaserod are warranted in PD-associated constipation.
Morgan
John C
JC
Movement Disorders Program, National Parkinson Foundation Center of Excellence, Department of Neurology, Medical College of Georgia, Augusta, GA, USA. jmorgan@msg.edu
Sethi
Kapil D
KD
D000368:Aged; D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*
D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod